Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (131-140 of 342) with videos related to

Pageof 35
Sort By:
Glia|February 17, 2017
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transportManuela De Bellis, Francesco Pisani, Maria Grazia Mola, et al.
Therapeutic Advances in Neurological Disorders|October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Therapeutic Advances in Neurological Disorders|July 12, 2023
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Muscle & Nerve|June 8, 2019
Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathyFrancesco Girolamo, Anna Lia, Tiziana Annese, et al.
European Cytokine Network|December 6, 2003
Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patientsVito Lampasona, Jordi Rio, Diego Franciotta, et al.
Plos One|May 5, 2012
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyPietro Iaffaldano, Rosa Gemma Viterbo, Damiano Paolicelli, et al.
Plos One|November 25, 2015
Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies DetectionFrancesco Pisani, Paolo Settanni, Stefania Rosito, et al.
Plos One|March 15, 2019
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null miceFrancesco Girolamo, Mariella Errede, Giovanna Longo, et al.
Trends in Pharmacological Sciences|June 29, 2004
Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection?Marco Cosentino, Mauro Zaffaroni, Maurizio Giorelli, et al.
Pageof 35

Showing results (131-140 of 342) with videos related to

Sort By:
Pageof 35
Glia|February 17, 2017
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transportManuela De Bellis, Francesco Pisani, Maria Grazia Mola, et al.
Therapeutic Advances in Neurological Disorders|October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Therapeutic Advances in Neurological Disorders|July 12, 2023
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Muscle & Nerve|June 8, 2019
Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathyFrancesco Girolamo, Anna Lia, Tiziana Annese, et al.
European Cytokine Network|December 6, 2003
Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patientsVito Lampasona, Jordi Rio, Diego Franciotta, et al.
Plos One|May 5, 2012
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyPietro Iaffaldano, Rosa Gemma Viterbo, Damiano Paolicelli, et al.
Plos One|November 25, 2015
Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies DetectionFrancesco Pisani, Paolo Settanni, Stefania Rosito, et al.
Plos One|March 15, 2019
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null miceFrancesco Girolamo, Mariella Errede, Giovanna Longo, et al.
Trends in Pharmacological Sciences|June 29, 2004
Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection?Marco Cosentino, Mauro Zaffaroni, Maurizio Giorelli, et al.
Pageof 35